13 research outputs found

    Immunotherapy in Multiple Myeloma

    No full text
    Multiple myeloma is a complex disease and immune dysfunction has been known to play an important role in the disease pathogenesis, progression, and drug resistance. Recent efforts in drug development have been focused on immunotherapies to modify the MM disease process. Here, we summarize the emerging immunotherapies in the MM treatment landscape

    Immunotherapy in Multiple Myeloma

    No full text
    10.3390/cells9030601CELLS9

    Genomic characterization of functional high-risk multiple myeloma patients

    No full text
    10.1038/s41408-021-00576-3BLOOD CANCER JOURNAL12

    Fibrillary Glomerulonephritis and Monoclonal Gammopathy: Potential Diagnostic Challenges

    No full text
    10.3389/fonc.2022.880923FRONTIERS IN ONCOLOGY1

    Potential Clinical Application of Genomics in Multiple Myeloma

    No full text
    Multiple myeloma is a heterogeneous disease with different characteristics, and genetic aberrations play important roles in this heterogeneity. Studies have shown that these genetic aberrations are crucial in prognostication and response assessment; recent efforts have focused on their possible therapeutic implications. Despite many emerging studies being published, the best way to incorporate these results into clinical practice remains unclear. In this review paper we describe the different genomic techniques available, including the latest advancements, and discuss the potential clinical application of genomics in multiple myeloma

    Immunoglobulin M Monoclonal Gammopathies of Clinical Significance

    No full text
    10.3389/fonc.2022.905484FRONTIERS IN ONCOLOGY1

    Surgical Management of Multiple Myeloma With Symptomatic Involvement of the Spine.

    No full text
    INTRODUCTION Multiple myeloma (MM) is the most frequent primary malignancy of the spine. We aimed to investigate the clinical presentation, surgical indications and outcomes, complications, survival, and its influencing factors in surgically treated MM patients with symptomatic involvement of the spine (SIS). METHODS Retrospective analysis of prospectively collected data. Out of 350 MM patients treated at our institution over a period of 12 years (2006-2018), we identified 24 patients who were surgically treated for SIS. We collected data on demographics, clinical presentation, comorbidities, surgical indications, and outcomes and investigated the factors predisposing to postoperative complications and survival. RESULTS The median follow-up duration was 85 months; median overall survival (OS) was 50 months. Clinical presentation at admission included pain (88%), sensory and/or motor deficit (67%), and bowel/bladder dysfunction (25%). Symptomatic pathological fractures were seen in 33%. Predominant surgical indications were rapid neurological deterioration with or without spinal cord compression (SCC), followed by mechanical instability. The majority of our patients benefited from surgery in terms of pain reduction in the short term as well as in the long term. There were 21% patients with surgical-related complications (<3 months). Surgical site infections occurred in 17%, without any obvious factors predisposing to infective complications. Neurological deterioration during hospital stay, especially in the presence of motor deficit and/or bowel/bladder dysfunction, significantly reduced OS. CONCLUSIONS Sudden-onset neurological deterioration was the predominant factor leading to surgery. We achieved good short- and long-term pain reduction. Surgery is a valuable option for MM patients with SIS who present with rapid neurological deterioration with or without SCC and/or mechanical instability

    Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis

    No full text
    10.1016/j.critrevonc.2020.103211CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY15
    corecore